vs
Side-by-side financial comparison of Phillips Edison & Company, Inc. (PECO) and Twist Bioscience Corp (TWST). Click either name above to swap in a different company.
Phillips Edison & Company, Inc. is the larger business by last-quarter revenue ($190.7M vs $103.7M, roughly 1.8× Twist Bioscience Corp). Phillips Edison & Company, Inc. runs the higher net margin — 17.4% vs -29.4%, a 46.8% gap on every dollar of revenue. On growth, Twist Bioscience Corp posted the faster year-over-year revenue change (16.9% vs 7.0%).
Consolidated Edison, Inc., commonly known as Con Edison or ConEd, is an energy company based in New York City. It is one of the largest investor-owned energy companies in the United States, with approximately $15.26 billion in annual revenues as of 2024, and over $70 billion in assets. The company provides a wide range of energy-related products and services to its customers through its subsidiaries:Consolidated Edison Company of New York, Inc. (CECONY), a regulated utility providing electric...
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
PECO vs TWST — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $190.7M | $103.7M |
| Net Profit | $33.2M | $-30.5M |
| Gross Margin | — | 52.0% |
| Operating Margin | 30.5% | -31.7% |
| Net Margin | 17.4% | -29.4% |
| Revenue YoY | 7.0% | 16.9% |
| Net Profit YoY | 15.1% | 3.4% |
| EPS (diluted) | $0.24 | $-0.50 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $190.7M | — | ||
| Q4 25 | $187.9M | $103.7M | ||
| Q3 25 | $182.7M | — | ||
| Q2 25 | $177.8M | — | ||
| Q1 25 | $178.3M | — | ||
| Q4 24 | $173.0M | — | ||
| Q3 24 | $165.5M | — | ||
| Q2 24 | $161.5M | — |
| Q1 26 | $33.2M | — | ||
| Q4 25 | $47.5M | $-30.5M | ||
| Q3 25 | $24.7M | — | ||
| Q2 25 | $12.8M | — | ||
| Q1 25 | $26.3M | — | ||
| Q4 24 | $18.1M | — | ||
| Q3 24 | $11.6M | — | ||
| Q2 24 | $15.3M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | 52.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | 30.5% | — | ||
| Q4 25 | — | -31.7% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | 17.4% | — | ||
| Q4 25 | 25.3% | -29.4% | ||
| Q3 25 | 13.5% | — | ||
| Q2 25 | 7.2% | — | ||
| Q1 25 | 14.8% | — | ||
| Q4 24 | 10.5% | — | ||
| Q3 24 | 7.0% | — | ||
| Q2 24 | 9.5% | — |
| Q1 26 | $0.24 | — | ||
| Q4 25 | $0.38 | $-0.50 | ||
| Q3 25 | $0.20 | — | ||
| Q2 25 | $0.10 | — | ||
| Q1 25 | $0.21 | — | ||
| Q4 24 | $0.16 | — | ||
| Q3 24 | $0.09 | — | ||
| Q2 24 | $0.12 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $3.1M | $197.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $2.3B | $456.1M |
| Total Assets | $5.4B | $638.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $3.1M | — | ||
| Q4 25 | $3.5M | $197.9M | ||
| Q3 25 | $4.1M | — | ||
| Q2 25 | $5.6M | — | ||
| Q1 25 | $5.5M | — | ||
| Q4 24 | $4.9M | — | ||
| Q3 24 | $6.4M | — | ||
| Q2 24 | $7.1M | — |
| Q1 26 | — | — | ||
| Q4 25 | $2.4B | — | ||
| Q3 25 | $2.4B | — | ||
| Q2 25 | $2.4B | — | ||
| Q1 25 | $2.3B | — | ||
| Q4 24 | $2.1B | — | ||
| Q3 24 | $2.1B | — | ||
| Q2 24 | $2.0B | — |
| Q1 26 | $2.3B | — | ||
| Q4 25 | $2.3B | $456.1M | ||
| Q3 25 | $2.3B | — | ||
| Q2 25 | $2.3B | — | ||
| Q1 25 | $2.3B | — | ||
| Q4 24 | $2.3B | — | ||
| Q3 24 | $2.2B | — | ||
| Q2 24 | $2.3B | — |
| Q1 26 | $5.4B | — | ||
| Q4 25 | $5.3B | $638.1M | ||
| Q3 25 | $5.3B | — | ||
| Q2 25 | $5.3B | — | ||
| Q1 25 | $5.2B | — | ||
| Q4 24 | $5.0B | — | ||
| Q3 24 | $5.0B | — | ||
| Q2 24 | $4.9B | — |
| Q1 26 | — | — | ||
| Q4 25 | 1.04× | — | ||
| Q3 25 | 1.05× | — | ||
| Q2 25 | 1.04× | — | ||
| Q1 25 | 0.99× | — | ||
| Q4 24 | 0.91× | — | ||
| Q3 24 | 0.94× | — | ||
| Q2 24 | 0.90× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $55.6M | $-24.8M |
| Free Cash FlowOCF − Capex | — | $-34.8M |
| FCF MarginFCF / Revenue | — | -33.5% |
| Capex IntensityCapex / Revenue | 12.6% | 9.6% |
| Cash ConversionOCF / Net Profit | 1.67× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $55.6M | — | ||
| Q4 25 | $348.1M | $-24.8M | ||
| Q3 25 | $95.4M | — | ||
| Q2 25 | $96.1M | — | ||
| Q1 25 | $60.5M | — | ||
| Q4 24 | $334.7M | — | ||
| Q3 24 | $109.1M | — | ||
| Q2 24 | $78.5M | — |
| Q1 26 | — | — | ||
| Q4 25 | — | $-34.8M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | -33.5% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | 12.6% | — | ||
| Q4 25 | — | 9.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | 1.67× | — | ||
| Q4 25 | 7.33× | — | ||
| Q3 25 | 3.87× | — | ||
| Q2 25 | 7.52× | — | ||
| Q1 25 | 2.30× | — | ||
| Q4 24 | 18.45× | — | ||
| Q3 24 | 9.40× | — | ||
| Q2 24 | 5.14× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PECO
| Rental income | $186.3M | 98% |
| Fees and management income | $3.4M | 2% |
TWST
| Industrial Chemicals | $37.2M | 36% |
| Diagnostics | $35.3M | 34% |
| Food Or Agriculture | $12.8M | 12% |
| Academic Research | $12.2M | 12% |
| Health Care | $6.1M | 6% |
